Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 4,157.1% in May

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 178,800 shares, an increase of 4,157.1% from the May 15th total of 4,200 shares. Approximately 1.7% of the shares of the company are short sold. Based on an average daily volume of 239,500 shares, the days-to-cover ratio is currently 0.7 days.

Armata Pharmaceuticals Trading Down 3.4%

Shares of NYSEAMERICAN ARMP traded down $0.07 during midday trading on Thursday, reaching $1.96. 6,985 shares of the company traded hands, compared to its average volume of 144,523. The business's 50-day moving average price is $1.55. Armata Pharmaceuticals has a 12 month low of $0.90 and a 12 month high of $3.42. The firm has a market capitalization of $70.91 million, a price-to-earnings ratio of -1.20 and a beta of 0.87.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their price objective on shares of Armata Pharmaceuticals from $7.00 to $9.00 and gave the company a "buy" rating in a research report on Monday, May 19th.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.